{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:10:28Z","timestamp":1754154628158,"version":"3.41.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>5-fluorouracil (5-FU) is a widely prescribed therapy for field cancerization. However, the emergence of cutaneous squamous cell carcinoma (cSCC) after 5-FU treatment is poorly described. We report five patients treated for field cancerization at four university hospitals between March 2019 and May 2021 who had eruptive cSCCs of varying severity following 5-FU. We examined the indications for treatment, immunosuppression status, onset of cSCCs, staging and outcomes. The patients (three female, two male; median age 74\u2005years) were treated with 5-FU for field cancerization. Four, including two solid-organ-transplant recipients, were on immunomodulating therapy. Eruptive cSCCs developed within 3 weeks to 3\u2005months of 5-FU treatment, mostly within the treated area. Staging revealed a spectrum of BWH T2b in two patients and BWH T1 in three. Eruptive cSCCs are a poorly characterized adverse event of topical 5-FU treatment. High-risk T-stage cSCCs, not yet reported and distinct from eruptive squamous atypia, may also develop despite low-grade background disease. Inflammation and immunomodulation could contribute to pathogenesis.<\/jats:p>","DOI":"10.1093\/ced\/llaf101","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T16:26:11Z","timestamp":1741105571000},"page":"1614-1619","source":"Crossref","is-referenced-by-count":1,"title":["Paradoxical development of reactive squamous atypia and\u00a0aggressive, invasive squamous cell carcinoma following 5-fluorouracil for field cancerization with concurrent immunomodulation"],"prefix":"10.1093","volume":"50","author":[{"given":"Erik","family":"Jaklitsch","sequence":"first","affiliation":[{"name":"School of Medicine, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren D","family":"Crow","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Petty","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgar","family":"Martinez","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, The University of Texas at Austin Dell Medical School , Austin, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melodi J","family":"Whitley","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A","family":"Myers","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Duke University Medical Center , Durham, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Feng","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth , Hanover, NH ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joi B","family":"Carter","sequence":"additional","affiliation":[{"name":"Geisel School of Medicine at Dartmouth , Hanover, NH ,","place":["USA"]},{"name":"Department of Dermatology, Dartmouth-Hitchcock Medical Center , , NH,","place":["Lebanon USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anokhi","family":"Jambusaria-Pahlajani","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, The University of Texas at Austin Dell Medical School , Austin, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei S","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonhan","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Pugliano-Mauro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pittsburgh Medical Center , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025072412171743600_llaf101-B1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jaad.2017.08.059","article-title":"Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging","volume":"78","author":"Que","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025072412171743600_llaf101-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines9020171","article-title":"Cutaneous squamous cell carcinoma: from pathophysiology to novel therapeutic approaches","volume":"9","author":"Fania","year":"2021","journal-title":"Biomedicines"},{"key":"2025072412171743600_llaf101-B3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/DSS.0000000000000760","article-title":"Fluorouracil-induced reactive follicular squamous cell carcinoma","volume":"42","author":"Meeks","year":"2016","journal-title":"Dermatol Surg"},{"key":"2025072412171743600_llaf101-B4","first-page":"55","article-title":"Reactive keratoacanthoma following treatment with 5-fluorouracil","volume":"16","author":"Paradkar","year":"2023","journal-title":"J Clin Aesthet Dermatol"},{"issue":"15 Suppl","key":"2025072412171743600_llaf101-B5","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.1200\/JCO.2018.36.15_suppl.9534","article-title":"Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: interim results of the phase 2 CARSKIN trial","volume":"36","author":"Maubec","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"2025072412171743600_llaf101-B6","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025072412171743600_llaf101-B7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jdcr.2019.03.014","article-title":"Eruptive squamous cell carcinomas in metastatic melanoma: an unintended consequence of immunotherapy","volume":"5","author":"Haraszti","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2025072412171743600_llaf101-B8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaad.2018.10.014","article-title":"Eruptive squamous atypia (also known as eruptive keratoacanthoma): definition of the disease entity and successful management via intralesional 5-fluorouracil","volume":"81","author":"Que","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025072412171743600_llaf101-B9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jdcr.2024.01.037","article-title":"Management of generalized eruptive keratoacanthomas: a case report and literature review","volume":"46","author":"Jordan","year":"2024","journal-title":"JAAD Case Rep"},{"key":"2025072412171743600_llaf101-B10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/12034754221143091","article-title":"Ingenol mebutate is associated with increased reporting odds for squamous cell carcinoma in actinic keratosis patients, a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"27","author":"Jedlowski","year":"2023","journal-title":"J Cutan Med Surg"},{"author":"European Medicines Agency","key":"2025072412171743600_llaf101-B11","article-title":"Picato \u2013 referral"},{"key":"2025072412171743600_llaf101-B12","first-page":"4068","article-title":"Inflammation: a key process in skin tumorigenesis","volume":"17","author":"Neagu","year":"2019","journal-title":"Oncol Lett"},{"key":"2025072412171743600_llaf101-B13","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/eji.201445052","article-title":"Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer","volume":"45","author":"Nardinocchi","year":"2015","journal-title":"Eur J Immunol"},{"key":"2025072412171743600_llaf101-B14","first-page":"261","article-title":"Overexpression of high-mobility motor box 1 in the blood and tissues of patients with head and neck squamous cell carcinoma","volume":"30","author":"Mohajertehran","year":"2018","journal-title":"Iran J Otorhinolaryngol"},{"key":"2025072412171743600_llaf101-B15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1245\/s10434-008-0237-z","article-title":"Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma","volume":"16","author":"Tateno","year":"2009","journal-title":"Ann Surg Oncol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf101\/62199325\/llaf101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1614\/62199325\/llaf101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1614\/62199325\/llaf101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:17:26Z","timestamp":1753373846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/8\/1614\/8045445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,2,27]]},"published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf101","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,2,27]]}}}